A Novel NF-kappa B-inducing Kinase-MAPK Signaling Pathway Up-regulates NF-kappa B Activity in Melanoma Cells
Overview
Authors
Affiliations
Constitutive activation of NF-kappa B is an emerging hallmark of various types of tumors including breast, colon, pancreatic, ovarian, and melanoma. In melanoma cells, the basal expression of the CXC chemokine, CXCL1, is constitutively up-regulated. This up-regulation can be attributed in part to constitutive activation of NF-kappa B. Previous studies have shown an elevated basal I kappa B kinase (IKK) activity in Hs294T melanoma cells, which leads to an increased rate of I kappa B phosphorylation and degradation. This increase in I kappa B-alpha phosphorylation and degradation leads to an approximately 19-fold higher nuclear localization of NF-kappa B. However, the upstream IKK kinase activity is up-regulated by only about 2-fold and cannot account for the observed increase in NF-kappa B activity. We now demonstrate that NF-kappa B-inducing kinase (NIK) is highly expressed in melanoma cells, and IKK-associated NIK activity is enhanced in these cells compared with the normal cells. Kinase-dead NIK blocked constitutive NF-kappa B or CXCL1 promoter activity in Hs294T melanoma cells, but not in control normal human epidermal melanocytes. Transient overexpression of wild type NIK results in increased phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which is inhibited in a concentration-dependent manner by PD98059, an inhibitor of p42/44 MAPK. Moreover, the NF-kappa B promoter activity decreased with overexpression of dominant negative ERK expression constructs, and EMSA analyses further support the hypothesis that ERK acts upstream of NF-kappa B and regulates the NF-kappa B DNA binding activity. Taken together, our data implicate involvement of I kappa B kinase and MAPK signaling cascades in NIK-induced constitutive activation of NF-kappa B.
Zhou Y, Yang Y, Tian R, Cheang W Sci Rep. 2025; 15(1):1542.
PMID: 39789118 PMC: 11718003. DOI: 10.1038/s41598-025-85144-6.
Korbecki J, Bosiacki M, Szatkowska I, Kupnicka P, Chlubek D, Baranowska-Bosiacka I Int J Mol Sci. 2024; 25(8).
PMID: 38673949 PMC: 11050300. DOI: 10.3390/ijms25084365.
Hwang B, Kim J, Park S, Chung H, Kim H, Choi Y World J Mens Health. 2024; 42(4):830-841.
PMID: 38606866 PMC: 11439794. DOI: 10.5534/wjmh.230200.
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar M, Kim H, Kim D Signal Transduct Target Ther. 2023; 8(1):455.
PMID: 38105263 PMC: 10725898. DOI: 10.1038/s41392-023-01705-z.
Revisiting the melanomagenic pathways and current therapeutic approaches.
Dhanyamraju P, Rotimi S, Bhattacharya P, Patel T Mol Biol Rep. 2022; 49(10):9651-9671.
PMID: 35397763 DOI: 10.1007/s11033-022-07412-2.